NASDAQ:ALKS - Nasdaq - IE00B56GVS15 - Common Stock - Currency: USD
27
-0.2 (-0.74%)
The current stock price of ALKS is 27 USD. In the past month the price decreased by -20.4%. In the past year, price increased by 13.21%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 318.82 | 36.40B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B |
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 1,800 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
ALKERMES PLC
Connaught House, 1 Burlington Road, Dublin 4
DUBLIN DUBLIN DUBLIN 4 IE
CEO: Richard F. Pops
Employees: 2100
Company Website: https://www.alkermes.com/
Investor Relations: https://investor.alkermes.com
Phone: 35317728000
The current stock price of ALKS is 27 USD. The price decreased by -0.74% in the last trading session.
The exchange symbol of ALKERMES PLC is ALKS and it is listed on the Nasdaq exchange.
ALKS stock is listed on the Nasdaq exchange.
22 analysts have analysed ALKS and the average price target is 40.36 USD. This implies a price increase of 49.49% is expected in the next year compared to the current price of 27. Check the ALKERMES PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ALKERMES PLC (ALKS) has a market capitalization of 4.45B USD. This makes ALKS a Mid Cap stock.
ALKERMES PLC (ALKS) currently has 2100 employees.
ALKERMES PLC (ALKS) has a support level at 26.68 and a resistance level at 33.8. Check the full technical report for a detailed analysis of ALKS support and resistance levels.
The Revenue of ALKERMES PLC (ALKS) is expected to decline by -7.75% in the next year. Check the estimates tab for more information on the ALKS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALKS does not pay a dividend.
ALKERMES PLC (ALKS) will report earnings on 2025-05-01, before the market open.
The PE ratio for ALKERMES PLC (ALKS) is 9.31. This is based on the reported non-GAAP earnings per share of 2.9 and the current share price of 27 USD. Check the full fundamental report for a full analysis of the valuation metrics for ALKS.
The outstanding short interest for ALKERMES PLC (ALKS) is 8.82% of its float. Check the ownership tab for more information on the ALKS short interest.
ChartMill assigns a technical rating of 1 / 10 to ALKS. When comparing the yearly performance of all stocks, ALKS is one of the better performing stocks in the market, outperforming 75.69% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to ALKS. ALKS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months ALKS reported a non-GAAP Earnings per Share(EPS) of 2.9. The EPS increased by 104.23% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 23.57% | ||
ROA | 17.86% | ||
ROE | 25.06% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to ALKS. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of -35.34% and a revenue growth -7.75% for ALKS